Vertex: Telaprevir Could Shorten Hep C Treatment
August 11, 2010
Some patients taking an experimental hepatitis C drug plus standard therapy achieved rapid, extended viral responses after a shortened course of therapy, Vertex Pharmaceuticals Inc. reported on Tuesday.
Vertex said patients who responded so well on telaprevir had better outcomes after 24 weeks than those who continued therapy for 48 weeks. The Phase III trial suggests that telaprevir plus standard therapy could be effective for some patients on just a 24-week regimen, Vertex said.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)